US · UNCY
Unicycive Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Los Altos, CA 94022
- Website
- unicycive.com
Price · as of 2024-12-31
$7.67
Market cap 148.94M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $18.82 | +145.37% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $13.10 | ||||
| 2022 | $26.80 | ||||
| 2023 | $15.20 | $6.08 | $0.00 | $0.00 | $244.07 |
| 2024 | $5.64 | $18.82 |
AI valuation
Our deep-learning model estimates Unicycive Therapeutics, Inc.'s (UNCY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $18.82
- Current price
- $7.67
- AI upside
- +145.37%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| UNCY | Unicycive Therapeutics, I… | $7.67 | 148.94M | +145% | — | — | — | -1.03 | 5.08 | — | -0.34 | -0.30 | 5.08 | 0.00% | — | — | -2028.11% | 209.66% | -160.18% | 0.10 | -452.35 | 1.28 | 1.08 | 0.70 | 33750.00% | -10000.00% | 5658.00% | -75.83% | -1.18 | 187.01% | 2.90% | -3.00% | 46.52% | -0.39 | -0.43 | — | -6.63 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| BMEA | Biomea Fusion, Inc. | $1.37 | 81.51M | — | — | — | — | -0.71 | 1.90 | — | -0.34 | -6.23 | 1.90 | 0.00% | — | — | -125.38% | -6089.18% | -98.92% | 0.17 | — | 3.15 | 2.69 | 0.35 | 1134.00% | — | 2030.00% | -122.90% | -5.53 | -5082.67% | 0.00% | 0.00% | 0.00% | -0.34 | -0.40 | — | -9.96 |
| CAMP | CAMP4 Therapeutics Corpor… | $4.49 | 95.37M | — | -59% | — | — | -1.58 | 1.29 | 125.35 | -0.51 | -0.81 | 1.29 | 100.00% | -8142.33% | -7943.40% | 719.97% | 75.53% | -57.27% | 0.14 | — | 6.92 | 6.68 | 1.08 | 19556.00% | — | 807.00% | -56.29% | -4.75 | 65.45% | 0.00% | 0.00% | 0.00% | -0.50 | -0.57 | 40.39 | -1.91 |
| CBUS | Cibus, Inc. | $3.69 | 194.57M | +439% | -76% | — | — | -0.18 | 0.56 | 12.04 | -0.30 | — | -0.26 | 100.00% | -6062.79% | -5898.36% | -146.63% | -129.39% | -63.21% | 0.39 | -7.56 | 0.85 | 0.78 | -0.09 | -5827.00% | 13456.00% | 1647.00% | -114.67% | -2.92 | -29.47% | 0.00% | 0.00% | 0.00% | -0.28 | -1.24 | 17.17 | -5.24 |
| HYFT | MindWalk Holdings Corp. | $1.13 | 52.76M | +1,308% | +315% | — | — | -2.28 | 2.92 | 2.84 | -2.48 | — | 4.82 | 47.31% | -50.47% | -123.30% | -105.08% | -30.71% | -57.90% | 0.57 | -1237.63 | 2.08 | 1.72 | -0.09 | -1262.00% | -203.00% | 2775.00% | -10.44% | -0.71 | -20.45% | 0.00% | 0.00% | 10.84% | -5.85 | -9.96 | 2.95 | -2.17 |
| IMUX | Immunic, Inc. | $1.02 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
- CEO
- Shalabh K. Gupta
- Employees
- 22
- Beta
- 1.84
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $7.67) − 1 = — (DCF, example).